OP White Papers - random

  1. Expanding The Capabilities Of Targeted Integration 5/1/2026

    See the demonstration of precise, site‑specific integration of a 50 kb multi‑gene construct into human iPSCs, overcoming size limits of traditional genome‑engineering approaches.

  2. Early Discovery Of Functional Antibody Leads 11/25/2025

    Early functional screening accelerates therapeutic antibody discovery, improving hit rates and efficiency through advanced platforms like hybridoma upgrades, single B cell workflows, and tailored phage display strategies.

  3. White Paper: Spray Drying Biologics: An Alternative To Freeze Drying 10/16/2024

    Explore how innovative drying technologies can enhance the stability and efficacy of biologics, ensuring successful outcomes in this rapidly growing sector of the pharmaceutical industry.

  4. The Relevance Of Polymorph Screening In The Pharmaceutical Industry 3/31/2025

    Polymorph screening identifies different solid forms of active pharmaceutical ingredients, optimizing drug stability, solubility, and manufacturability. This process ensures quality, regulatory compliance, and intellectual property protection in pharmaceutical development.

  5. A Platform That's Revolutionizing Biopharma Manufacturing 5/26/2026

    Integrated platform boosts biologics manufacturing by raising protein yield, speeding timelines, and improving scalability via cell line development, process optimization, and data-driven design.

  6. Key Selection Criteria For Cell & Gene Therapy CDMOs 3/4/2026

    Choosing the right CDMO requires early internal assessment plus strong technical capability, agility, advocacy, clear communication, and long‑term alignment to meet evolving cell and gene therapy needs.

  7. Project Management: Sphere Of Influence 10/21/2024

    The project manager's sphere of influence extends beyond the project team, encompassing the organization, industry, and professional discipline.

  8. Flexible Fill/Finish Solutions To Bridge The Clinical-To-Commercial Gap 7/23/2025

    As biopharma complexity grows, flexible CDMOs are essential for navigating evolving fill/finish needs, accelerated timelines, and regulatory uncertainty with agility and expertise.

  9. Activate Advanced Contamination Control Technology To Safeguard Your Cell Therapy 2/6/2026

    The most common contamination risks in cell therapy manufacturing are open processes that leverage different products, inflexible instruments, labor intensive workflows, lack of in-line monitoring, and zero failure tolerance.

  10. A Cell Line Development Platform Accelerating Timelines To Clinic 3/20/2026

    To support a seamless transition from early clinical studies through to commercial manufacturing, cell line expression systems must be carefully designed and selected based on several critical attributes.